Consensus Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 13/06/2025 BST			5-day change	1st Jan Change
1,481.00 ^DKK	-0.20%		+2.46%	-0.77%

06-09	Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM
06-09	AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	MT

Evolution of the Average Target: Genmab A/S

Evolution of the Target Price: Genmab A/S

Changes in Analyst Recommendations: Genmab A/S

7fd09.hNZ9ptYRtOqvdTlrz01xTTsS6Kzm1f79udUcgi4AvxY.9K4366do44iZAmtbpz9DGnhhnciElsyl-5It7n13j0Xn7hjR4HviqPsFWg~57ce80de300723d1e84a8c6dfb102ee6

Analysts' recommendations: Genmab A/S

GENMAB : Beaten up share price offers an opportunity	06-06
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	05-30	FW
RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating	05-29	MT
Deutsche Bank lowers target price for Genmab to DKK 1,750 (1,900), reiterates buy recommendation	05-23	FW
Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation - BN	05-23	FW
UBS lowers target price for Genmab to DKK 2,600 (2,700), reiterates buy recommendation	05-12	FW
GENMAB : Mixed Q1; guidance maintained	05-10
Nordea Bank Upgrades Genmab to Buy	05-09	MT
Nykredit lowers target price for Genmab to DKK 1,750 (2,000), reiterates buy recommendation - BN	05-09	FW
Nordea raises Genmab to buy (hold), target price SEK 2,009	05-09	FW
Goldman Sachs raises target price for Genmab to DKK 1,785 (1,764), reiterates neutral rating - BN	05-09	FW
Carnegie raises target price for Genmab to DKK 2,288 (2,263), reiterates buy recommendation - BN	05-09	FW
Cowen lowers target price for Genmab to DKK 1,360 (1,431), reiterates hold rating - BN	05-09	FW
Svenska Handelsbanken Upgrades Genmab to Buy, Boosts PT	05-07	MT
Handelsbanken raises Genmab to buy (hold), target price SEK 2,000 (1,350)	05-07	FW
Carnegie lowers target price for Genmab to DKK 2,263 (2,491), reiterates buy recommendation - BN	05-06	FW
HSBC lowers target price for Genmab to DKK 1,990 (2,970), reiterates buy recommendation - BN	04-28	FW
Goldman Sachs lowers target price for Genmab to DKK 1,764 (1,841), reiterates neutral - BN	04-22	FW
BNP Paribas Exane lowers target price for Genmab to DKK 1,300 (1,400), reiterates neutral - BN	04-16	FW
Bernstein Downgrades Genmab to Underperform, Cuts PT	04-01	MT
Bernstein downgrades Genmab to underperform (market perform), target price DKK 1,000 (1,580) - BN	04-01	FW
BNP Paribas Exane lowers target price for Genmab to DKK 1,400 (1,500), reiterates neutral - BN	03-12	FW
William Blair Upgrades Genmab to Outperform From Market Perform	03-11	MT
RBC Cuts Price Target on Genmab to DKK2,300 From DKK2,400, Keeps Outperform Rating	03-11	MT
Goldman Sachs lowers target price for Genmab to DKK 1,841 (2,064), reiterates neutral - BN	03-11	FW

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	GENMAB A/S					+31.16%
	REGENERON PHARMACEUTICALS, INC.					+37.41%
	ARGENX SE					+33.38%
	BEONE MEDICINES LTD.					+23.12%
	WUXI APPTEC CO., LTD.					+21.29%
	BIONTECH SE					+27.24%
	INSMED INCORPORATED					+9.85%
	SUMMIT THERAPEUTICS INC.					+76.14%
	WUXI BIOLOGICS (CAYMAN) INC.					+4.4%
	EXELIXIS, INC.					-0.66%
	Average					+26.33%
	Weighted average by Cap.					+28.36%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,481.00DKK

Average target price

1,942.52DKK

Spread / Average Target

+31.16%

High Price Target

2,700.00DKK

Spread / Highest target

+82.31%

Low Price Target

1,000.00DKK

Spread / Lowest Target

-32.48%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

alphavalue	Anas Patel
RBC Capital Markets
Nordea Bank
Svenska Handelsbanken
Bernstein
William Blair & Co.
Truist Securities
Leerink Partners
BNP Paribas
Redburn Atlantic
BMO Capital
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group